Max Robotics — Global Service Robot Directory + US Certification

About

H. Alheit is a prominent radiation oncologist whose research has significantly advanced stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer (NSCLC). Her most cited work, the 2017 "Planning benchmark study for SBRT of early stage NSCLC" (54 citations), established critical dosimetric and planning guidelines that have become a standard reference in the field. This study systematically evaluated target delineation, dose constraints, and treatment plan quality across multiple institutions, directly improving the reproducibility and safety of SBRT delivery. Beyond this benchmark, Alheit's contributions span clinical trial design, normal tissue complication modeling, and the integration of advanced imaging into treatment planning. Her research has helped refine SBRT as a definitive, non-invasive option for medically inoperable NSCLC patients, reducing treatment-related toxicity while maintaining high local control rates. With a career dedicated to translating technical innovation into tangible patient benefit, Alheit remains an influential voice in thoracic radiation oncology, shaping both clinical practice and quality assurance standards worldwide.